Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Hydreight Technologies Inc ( (TSE:NURS) ) has shared an announcement.
Hydreight Technologies has entered the at-home sexually transmitted infection pre-screening market through an exclusive distribution agreement with Health Screen Collective, making Hydreight the sole distributor of HSC’s rapid at-home STI pre-screen testing kits across its national platform and securing about 50,000 pre-orders for delivery starting in early 2026. The partnership gives Hydreight a foothold in a high-frequency, repeat-use healthcare segment by offering rapid, minutes-based at-home pre-screening for multiple common infections, backed by lateral-flow immunoassay technology with lab-comparable performance, and integrates results directly into Hydreight’s digital ecosystem for licensed medical review, confirmatory testing and treatment coordination, enhancing its platform-first strategy and strengthening its role in scalable, end-to-end digital care solutions.
The most recent analyst rating on (TSE:NURS) stock is a Buy with a C$8.50 price target. To see the full list of analyst forecasts on Hydreight Technologies Inc stock, see the TSE:NURS Stock Forecast page.
More about Hydreight Technologies Inc
Hydreight Technologies Inc. is a U.S.-focused digital health platform that enables on-demand care, pharmacy fulfillment and enterprise healthcare services through a national network. The company’s model centers on connecting consumers with licensed providers and integrated clinical workflows, positioning Hydreight to capitalize on the growing shift toward remote and at-home healthcare solutions.
Average Trading Volume: 131,351
Technical Sentiment Signal: Buy
Current Market Cap: C$124.6M
For detailed information about NURS stock, go to TipRanks’ Stock Analysis page.